Article Text

Download PDFPDF
Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs
  1. W W Bolten
  1. Correspondence to:
    Dr W W Bolten
    Klaus Miehlke-Klinik, Rheumatology, Leibnizstr. 23, 65191 Wiesbaden, Germany;


Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profile of selective COX-2 inhibitors, but also the potential atherothrombotic risk of any NSAID or selective COX-2 inhibitor treatment.

  • APC, Adenoma Prevention with Celecoxib
  • APPROVe, Adenomatous Polyp Prevention on Vioxx
  • ASA, acetylsalicylic acid
  • bid, twice a day
  • CABG, Coronary Artery Bypass Graft
  • CI, confidence interval
  • CLASS, Celecoxib Long term Arthritis Safety Study
  • COX-2, cyclo-oxygenase-2
  • CV, cardiovascular
  • GI, gastrointestinal
  • IV, intravenous
  • MI, myocardial infarction
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • PGI2, prostaglandin I2
  • PPI, proton pump inhibitor
  • PreSAP, Prevention of Spontaneous Adenoma Polyps
  • RA, rheumatoid arthritis
  • tid, three times a day
  • TARGET, Therapeutic Arthritis Research and Gastrointestinal Event Trial
  • TXA2, thromboxane A2
  • VIGOR, Vioxx Gastrointestinal Outcomes Research
  • non-steroidal anti-inflammatory drugs
  • atherothrombotic risk
  • COX-2 inhibitors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.